Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.

ABSTRACT:

Background and objectives

Janus kinase (JAK) inhibitors are emerging as a therapeutic option for alopecia areata. The risk of potential adverse events is currently debated. In particular, several safety data for JAK inhibitors are extrapolated from a single study in elderly patients with rheumatoid arthritis treated with tofacitinib or adalimumab/etanercept as a comparator. The population of patients with alopecia areata is clinically and immunologically different from persons with rheumatoid arthritis and tumor necrosis factor (TNF) inhibitors are not effective in these patients. The objective of this systematic review was to analyze available data on the safety of various JAK inhibitors in patients with alopecia areata.

Methods

The systematic review was performed according

SUBMITTER: Papierzewska M 

PROVIDER: S-EPMC10155665 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature